Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2135-2137

  Ou, Sai Hong Ignatius ^a   Azada, Michele ^a   Dy, Joni ^a   Stiber, Jonathan A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Crizotinib (PF02341066); Non small cell lung cancer; Pharmacodynamic effect; Sinus bradycardia

Indexed keywords

CRIZOTINIB;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANCER PATIENT; CASE REPORT; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROFOUND SINUS BRADYCARDIA; QT PROLONGATION; SINUS BRADYCARDIA;

ADULT; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; BRADYCARDIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 81755188353     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182307e06     Document Type: Article

References (6)

1. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
2. Ou SHI, Bazhenova L, Camidge DR, et al. Rapid and dramatic radiographic and clinical response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010;5:2044-2046.
3. Ou SHI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6:942-946.
4. Mellor HR, Bell AR, Valentin J-P, et al. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011;120:14-32.
5. Nickens D, Tan W, Wilner K, et al. A pharmacokinetics/pharmacodynamics evaluation of the concentration-QTc relationship of PF-02341066 (PF-1066), an ALK and c-MET/HGFR dual inhibitor administered to patients with advanced cancer. Poster presented at the 101st annual meeting of the American Association for Cancer Research, Washington, DC, USA, April 17-21, 2010 (abstract # 1673).
6. Surawicz B, Knilans TK. Chou's Electrocardiography in Clinical Practice, 5th Ed. Philadelphia, PA: WB Saunders, 2011.